OrthoPediatrics (NASDAQ:KIDS) Stock Price Down 3.5% – Should You Sell?

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) dropped 3.5% during trading on Thursday . The company traded as low as $22.44 and last traded at $22.3490. 44,246 shares traded hands during trading, a decline of 75% from the average daily volume of 174,151 shares. The stock had previously closed at $23.15.

Analyst Ratings Changes

KIDS has been the topic of several research reports. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. BTIG Research reissued a “buy” rating and set a $29.00 target price on shares of OrthoPediatrics in a report on Monday, September 14th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Finally, Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics Trading Up 0.2%

The company has a market cap of $569.72 million, a price-to-earnings ratio of -12.99 and a beta of 0.99. The firm has a 50 day moving average price of $22.25 and a two-hundred day moving average price of $19.22. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The company had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. As a group, equities analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Insider Transactions at OrthoPediatrics

In other news, Director David R. Pelizzon sold 326,700 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the sale, the director directly owned 6,536,764 shares in the company, valued at $150,607,042.56. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Jennifer N. Pritzker sold 326,700 shares of OrthoPediatrics stock in a transaction on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the insider directly owned 6,536,764 shares of the company’s stock, valued at $150,607,042.56. This represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Company insiders own 32.50% of the company’s stock.

Institutional Trading of OrthoPediatrics

Large investors have recently bought and sold shares of the business. Waverly Advisors LLC lifted its stake in shares of OrthoPediatrics by 6.7% in the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock valued at $237,000 after purchasing an additional 775 shares during the period. Legal & General Group Plc acquired a new stake in OrthoPediatrics during the second quarter worth approximately $34,000. Quantinno Capital Management LP bought a new stake in OrthoPediatrics in the first quarter worth approximately $160,000. FourThought Financial Partners LLC bought a new stake in OrthoPediatrics in the fourth quarter worth approximately $197,000. Finally, R Squared Ltd acquired a new position in OrthoPediatrics in the first quarter valued at approximately $212,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.